n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Biotech Mailbag Bonus: Elan Story Causes Stir

Response over the company's new Alzheimer drug endpoint has been both critical and supportive.

Tomorrow's Headliners: Fed Bankers

Also, data on personal income and spending, the Chicago PMI and the University of Michigan's revised consumer sentiment survey are all on the schedule.

Wednesday's Health Winners & Losers

Biogen and Elan take hits on a new Tysabri warning.

Elan, Wyeth Play by Own Rules in Alzheimer's Trial

The drugmakers are using a new and unproven endpoint for their closely watched bapineuzumab drug.

Tomorrow's Headliners: Bernanke Speaks

Also, Adam Feuerstein will take a look at Elan.

'Fast Money' Recap: Going Global

Some in the crew say the global story is back.

'Mad Money Lightning Round': Elan for Elan

Cramer wishes he had bought shares in the Irish biotech.

Biogen Profits Trounce Targets

The biotech company delivers better-than-expected fourth-quarter and year-end earnings and sales.

Medivation Rallies, but Skeptics Clamor for Caution

Fans and foes of the company's Alzheimer's drug stick to their guns.

FDA OKs Tysabri for Crohn's

The drug, a 50/50 venture between Biogen and Elan, is cleared to treat the rare disease.

Biotech Preview: Genzyme, Biogen, Amgen, Celgene

Here's an overview of the outlooks offered at last week's JPMorgan confab and a look at what's to come.

Biogen Idec Bears Good Guidance News

It ups guidance.

Monday's Daily Blog Watch

Stock picks for 2008, making heads and tails of subprime, and more.

Biotech's Winners and Losers for '08

The biotech sector hinges on presidential race, FDA and mergers.

Biotech Trial Dates to Watch in '08

Myriad Genetics and Dendreon are among those with major clinical trials next year.

Biotech Stocks Face Make-or-Break FDA Rulings

Several drugmakers face key approval votes in 2008.

Cramer's 'Mad Money Lightning Round': Ride the Tidewater

Cramer says to pull the trigger while the oil service stock is cheap.

Feuerstein's Biotech-Stock Mailbag

Waiting for a Biogen buyout means weathering the volatility.

Friday's Health Winners & Losers

Coley Pharma soars on a buyout deal.

Monday's Health Winners & Losers

Adam's Therapeutics rises.

Monday's Health Winners & Losers

Biogen Idec surges on buyout talk.

FDA Extends Tysabri Review

A decision on the drug's use as a Crohn's disease treatment is likely by Jan. 13.

Biotech Stock Earnings Preview

A sneak peak at which names in the sector will be reporting results in the coming two weeks.

What's Biogen Worth?

What's Biogen Worth?

The company could fetch top dollar, depending on what buyers believe.

Biogen Idec Seeks Buyer

It has already received some expressions of interest, including one from Carl Icahn.

Alzheimer's Drug Stocks May Be Worth Wait

The payoff may come later, but these focused companies should still get a look.

Hoping for a Big Surge

It would provide a clear signal of the negative divergences going into next week.

Feuerstein's Biotech-Stock Mailbag

What's up with Elan and Tysabri?

Thursday's Health Winners & Losers

Anesiva climbs on a licensing deal.

Feuerstein's Biotech-Stock Mailbag

This week, questions on Vertex Pharmaceuticals, Novacea and more.